Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment.

Journal of medicine and life

Volumn 3, Issue 2, 2010, Pages 162-166

  Bumbea, Horia ^a   Vladareanu, Ana Maria ^b   Voican, Irina ^b   Cisleanu, Diana ^b   Barsan, Lavinia ^b   Onisai, Minodora ^b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; DASATINIB; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HUMAN; ONCOGENE; REVIEW;

DRUG RESISTANCE, NEOPLASM; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 79952058441     PISSN: 1844122X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)